-
Product Insights
New![]()
Net Present Value Model: bluebird bio Inc’s Iovotibeglogene Autotemcel
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: bluebird bio Inc’s Iovotibeglogene Autotemcel
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Heartland RE – Trousdale Ferry Pike and Bluebird Road Residential Development – Tennessee
Equip yourself with the essential tools needed to make informed and profitable decisions with our Heartland RE - Trousdale Ferry Pike and Bluebird Road Residential Development - Tennessee report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
Bluebird Self Storage/ NYX Cap – Montreal Self Storage Facility Redevelopment – Quebec
Equip yourself with the essential tools needed to make informed and profitable decisions with our Bluebird Self Storage/ NYX Cap - Montreal Self Storage Facility Redevelopment - Quebec report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Company Profile
![]()
bluebird bio Inc – Company Profile
bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD), betibeglogene autotemcel for transfusion-dependent beta thalassemia, Lovo-cel for the treatment of sickle cell disease, besides compounds under development...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lovotibeglogene Autotemcel in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lovotibeglogene Autotemcel in Sickle Cell Disease Drug Details: Lovotibeglogene autotemcel (bb1111) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RNAi Gene Therapy to Inhibit BCL11A for Sickle Cell Disease and Beta Thalassemia in Sickle Cell Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RNAi Gene Therapy to Inhibit BCL11A for Sickle Cell Disease and Beta Thalassemia in...
-
Product Insights
New![]()
Cell & gene therapy in pharma: lentiviral vectors
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s lentiviral vectors within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with...
-
Product Insights
Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Adrenoleukodystrophy Clinical Trials Analysis Overview The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) clinical trial market research report provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M&A in the Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry...
-
Product Insights
Thalassemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Thalassemia Clinical Trials Market Report Overview The Thalassemia clinical trial market research report provides an overview of the Thalassemia clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Track & Monitor
Innovation in Pharmaceuticals: Viral vectors
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Bluebird Solar PV Plant
Bluebird solar PV Plant is a 90MW solar PV power project located in Kentucky, United States. It is being developed by Bluebird Solar LLC. The project is currently in the permitting stage. The project is owned by Bluebird Solar LLC. Bluebird solar PV Plant profile includes core details such as plant name, technology, capacity, status, plant proponents (owners, developers etc.), owner stakes etc as well as key operational data including generation, year online, decommissioning year, capital expenditure etc. Details on...
-
Product Insights
![]()
Net Present Value Model: Iovotibeglogene Autotemcel
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Iovotibeglogene Autotemcel Drug Details Lovotibeglogene autotemcel...
-
Product Insights
![]()
Net Present Value Model: Zynteglo
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Zynteglo Drug Details Zynteglo (betibeglogene autotemcel)...
-
Product Insights
![]()
Net Present Value Model: Skysona
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Skysona Drug Details Elivaldogene autotemcel (Skysona)...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Track & Monitor
![]()
Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.